---
title: "HWHG: Dapoxetine Hydrochloride Tablets have obtained the drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260871540.md"
description: "HWHG's subsidiary Jiulong HWHG recently obtained the drug registration certificate for Dapoxetine Hydrochloride Tablets approved by the National Medical Products Administration. This drug is used to treat male premature ejaculation. Jiulong HWHG submitted the marketing authorization application in July 2024, with research and development investment of approximately 10 million yuan, and production entrusted to Chongqing Boteng Pharmaceutical Co., Ltd. The national sales are expected to be around 1.1 billion yuan in 2024, with major competitors including Shandong Huabokai Sheng Biotechnology Co., Ltd. and others"
datetime: "2025-10-13T09:47:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260871540.md)
  - [en](https://longbridge.com/en/news/260871540.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260871540.md)
generator: "portal-rs"
---

# HWHG: Dapoxetine Hydrochloride Tablets have obtained the drug registration certificate

According to the Zhitong Finance APP, HWHG (600079.SH) announced that its controlling subsidiary, Wuhan Jiulong HWHG Pharmaceutical Co., Ltd. (hereinafter referred to as "Jiulong HWHG," which is 100% owned by its controlling subsidiary Hubei Gedian HWHG Pharmaceutical Co., Ltd.), recently received the "Drug Registration Certificate" for Dapoxetine Hydrochloride Tablets issued by the National Medical Products Administration.

Dapoxetine Hydrochloride Tablets are used to treat male premature ejaculation (PE). Jiulong HWHG submitted the application for the marketing authorization of Dapoxetine Hydrochloride Tablets to the National Medical Products Administration in July 2024 and received acceptance. As of now, the cumulative R&D investment is approximately RMB 10 million. Jiulong HWHG has entrusted Chongqing Boteng Pharmaceutical Co., Ltd. to produce Dapoxetine Hydrochloride Tablets. According to data from Minet, the national sales of Dapoxetine Hydrochloride Tablets for the year 2024 (the statistical scope includes urban public hospitals, county-level public hospitals, urban pharmacies, and online pharmacies) is approximately RMB 1.1 billion, with major manufacturers including Shandong Huabokai Sheng Biotechnology Co., Ltd. (entrusted to Yantai Luyin Pharmaceutical Co., Ltd. for production), Sichuan Kelun Pharmaceutical Co., Ltd., and Berlin-Chemie AG

### Related Stocks

- [600079.CN](https://longbridge.com/en/quote/600079.CN.md)

## Related News & Research

- [Humanwell unit Yichang Renfu wins China nod for labor pain trial of sufentanil injection](https://longbridge.com/en/news/295637927.md)
- [YUSHU TECHNOLOGY Founder Wang Xingxing Says Humanoid Robots' 'ChatGPT Moment' May Still Be a Decade Away; Nomura Initiates Coverage with Buy Rating](https://longbridge.com/en/news/296462640.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [China's Daqo New Energy Q2 revenue falls on weak demand](https://longbridge.com/en/news/296476125.md)
- [Innova Captab Revises FY26 Accounts and Clears Baddi Plant Expansion](https://longbridge.com/en/news/296661728.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**